90956-78-8

Basic information

• Product Name: 1-Propanone, 2,3-dibromo-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-
• CAS NO: 90956-78-8
• Molecular Formula: C16H13Br2ClO2
• Molecular Weight: 432.539
• Mol File: 90956-78-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Propanone, 2,3-dibromo-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanone, 2,3-dibromo-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-(90956-78-8)
• EPA Substance Registry System: 1-Propanone, 2,3-dibromo-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-(90956-78-8)

Safety Data

• Hazardous Substances Data: 90956-78-8(Hazardous Substances Data)

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 6552-63-2 4'-chloro-4-methoxy-chalcone 
• 85502-87-0 (E)-4'-chloro-4-methoxychalcone 

Downstream Products

• 37975-19-2 1-(4-chlorophenyl)-3-(4-methoxyphenyl)propane-1,3-dione 
• 173319-15-8 2-bromo-1-(4-chlorophenyl)-3-(4-methoxyphenyl)propane-1,3-dione 
• 121830-20-4 4-(4-Chloro-phenyl)-6-(4-methoxy-phenyl)-[1,3]thiazin-2-ylideneamine 
• 135549-10-9 2-bromo-3-(4-methoxyphenyl)-1-(4-chlorophenyl)-2-propen-1-one 
• 6552-63-2 4'-chloro-4-methoxy-chalcone 
• 101602-36-2 4-(4-chloro-phenyl)-2-(4-methoxy-phenyl)-4-oxo-butyronitrile 
• 101570-94-9 2-bromo-1-(4-chloro-phenyl)-3-methoxy-3-(4-methoxy-phenyl)-propan-1-one 
• 135549-24-5 6-(4-Chloro-phenyl)-3-ethyl-8-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine 

Relevant articles and documents

New nicotinic acid-based 3,5-diphenylpyrazoles: design, synthesis and antihyperlipidemic activity with potential NPC1L1 inhibitory activity

Nicotinic acid hydrazide was incorporated into new 4,5-dihydro-5-hydroxy-3,5-diphenylpyrazol-1-yl derivatives. Compounds 6a–h were synthesized, and their antihyperlipidemic activity was evaluated in high cholesterol diet-fed rat model. Compounds 6e, 6f were found to decrease the levels of serum total cholesterol by 14–19% compared to control group. Total triglycerides were also reduced by 24–28% and LDL cholesterol by 16%. As expected from parent niacin, compounds 6e and 6f caused an elevation of HDL cholesterol by 33–41%. Docking study supported the ability of designed compounds to block NPC1L1 active site in a manner similar to that observed with ezetimibe.

A new synthetic strategy towards 2,4,5-trisubstituted 1H-imidazoles and highly substituted pyrrolo[1,2-c]imidazoles by use of α-azidochalcones via Michael addition-cyclization followed by Wittig reaction

Efficient and facile protocols for the preparation of highly functionalized 1H-imidazoles and 5H-pyrrolo[1,2-c]imidazoles are described. Heating a mixture of an α-azidochalcones and N,N,N′,N′-tetramethyl guanidine under neat conditions gave the corresponding 2,4,5-trisubstituted 1H-imidazole via Michael addition-cyclization in excellent yields. Subsequently, the prepared 1H-imidazoles undergo addition-Wittig reaction with acetylenic esters in presence of triphenylphosphine in dichloromethane to afford 5H-pyrrolo[1,2-c]imidazoles in high yields.

Imidazo[2,1-b]thiazole derivatives XII. Synthesis and immunoactivity in vitro on human T lymphocyte of several 3-aroylmethyl and 2-aroyl-3-methyl(aryl)-5,6-dihydroimidazo[2,1-b]thiazoles

To estimate the influence of aryl group position on the immunostimulant properties of imidazo[2,1-b]thiazole derivatives, several compounds were obtained and tested, versus tetramisole hydrochloride, on the mobilisation of CD2 receptor by human T lymphocyte. The synthesis use the action of monobrominated β-diketones on the 2-mercaptoimidazoline. So, 1-aryl-4-bromobutane-1,3-diones lead to 3-aroylmethyl-5,6-dihydroimidazo[2,1-b]thiazoles 4. Same, 1-aryl-2-bromobutane-1,3-diones and 1,3-diaryl-2-bromopentane-1,3-diones give respectively 3-aroyl-2-methyl-5,6-dihydroimidazo[2,1-b]thiazoles 5 and 3-aroyl-2-aryl-5,6-dihydroimidazo[2,1-b]thiazoles 6. Better yields are obtained when the reaction presents two steps. The first one, realized in acetone at room temperature, leads to an intermediate S-substituted 4,5-dihydroimidazole which, in second step, is cyclized in imidazo[2,1-b]thiazole compound via an unisolated carbinolamine. This one explains the univocal formation of 5 derivatives and the feasible blending in case of 6. The immunoactivity of several imidazothiazoles 4, 5 and 6 is lower that them of 6-aryl substituted compounds and particularly that the levamisole which is the reference product in this series.